2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]恶唑啉-2-基]吡啶

2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]恶唑啉-2-基]吡啶性质、用途与生产工艺

2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]恶唑啉-2-基]吡啶 上下游产品信息

上游原料

下游产品

2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]恶唑啉-2-基]吡啶 生产厂家

185346-09-2, 2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]恶唑啉-2-基]吡啶 相关搜索:

• organic amine
• Chiral Nitrogen
• BOX series
• 高端化学
• 化学试剂
• 化学连接
• 有机配体
• 氮配体
• (-)-2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]噁唑啉-2-基]吡啶
• 人眼黑色素瘤细胞
• 2,6-双[(3AS,8AR)-(-)-8H-茚并[1,2-D]噁唑啉-2-基]吡啶, 用于合成
• 2,6-双[(3AS,8AR)-3A,8A-二氢-8H-INDENO[1,2-D]恶唑啉-2-基]吡啶
• (3AS,3'AS,8AR,8'AR)-2,2'-(2,6-吡啶二基)双[3A,8A-二氢-8H-茚并[1,2-D]恶唑]
• 2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]恶唑啉-2-基]吡啶
• 2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]噁唑啉-2-基]吡啶
• (3AS,3′AS,8AR,8′AR)-2,2′-(2,6-吡啶二基)双[3A,8A-二氢-8H-茚并[1,2-D]唑
• (-)-2,6-双[2-{3AS-(2(3'AR*,8'AS*),3AΑ,8AΑ)-3A,8A-二氢-8H-茚并[1,2-D]噁唑啉-2-基}]吡啶
• 2,6-双[(3AS,8AR)-(-)-8H-茚并[1,2-D]噁唑啉-2-基]吡啶
• 2,6-双[(3AS,8AR)-3A,8A-二氢-8H-茚并[1,2-D]唑啉-2-基]吡啶
• 185346-09-2
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aα,8aα)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine
• (-)-2,6-BIS[2-[3AS-(2(3'AR*,8'AS*),3A,8A)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE]]PYRIDINE
• (-)-2,6-Bis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-d]oxazolin-2-yl]pyridine
• (-)-2,6-BIS[2-[3AS-(2(3'AR*,8'AS*),3A,8A)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE]]PYRIDINE
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aα,8aα)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine,97%
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aα,8aα)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine
• (-)-2,6-BIS[2-[3AS-(2(3'AR*,8'AS*),3A,8A)-3A,8A-DIHYDRO-8H-I...
• (S,R)-In-Pybox
• 8H-Indeno[1,2-d]oxazole, 2,2'-(2,6-pyridinediyl)bis[3a,8a-dihydro-, (3aS,3'aS,8aR,8'aR)-
• 2,6-Bis[(3aS,8aR)-(-)-8H-indeno[1,2-d]oxazolin-2-yl)]pyridine, 98%, for synthesis
• (-)-2,6-Bis[2-[3as-(2(3'ar*,8'as*),3a alpha,8aalpha)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole]]pyridine
• (3aS,3'aS,8aR,8'aR)-2,2'-(2,6-Pyridinediyl)bis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole], 95%, (99% ee)
• [3aS-[2(3'aRS,8'aSR),3aα,8aα]]-2,2'-(2,6-pyridinediyl)bis-[3a,8a-dihydro-8H-indeno[1,2-d]oxazole]
• SF150006
• (3aR,8bS)-2-[6-[(3aR,8bS)-4,8b-dihydro-3aH-indeno[1,2-d][1,3]oxazol-2-yl]pyridin-2-yl]-4,8b-dihydro-3aH-indeno[1,2-d][1,3]oxazole
• (-)-2,6-BIS[(3AS,8AR)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLIN-2-YL]PYRIDINE,MIN.97%INDENYL-PYBOX
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aα,8aα)-3a,8a-dihydro-8H-indeno [1,2-d]oxazole}]pyridine, min. 97%　
• (-)-2,6-BIS[2-[3AS-(2(3'AR*,8'AS*),3A,8A)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE]]PYRIDINE
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aalpha:,8aalpha:)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine, min. 97%
• 2,6-Bis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-d]oxazolin-2-yl]pyridine
• (3aS,8aR)-in-pybox, (3aS,3μaS,8aR,8μaR)-2,2μ-(2,6-Pyridinediyl)bis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aalpha,8aalpha)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine,min.97%
• 2,6-BIS((3AS,8AR)-8H-INDENO(1,2-D)OXAZO&
• (3aS,8aR)-in-pybox
• 2,6-Bis[(3aS,8aR)-(-)-8H-indeno[1,2-d]oxazolin-2-yl)]pyridine
• (-)-2,6-BIS[2-{3AS-(2(3'AR*,8'AS*),3AΑ,8AΑ)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE}]PYRIDINE
• (3aS,3'aS,8aR,8'aR)-2,2'-(2,6-Pyridinediyl)bis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole],99%e.e.
• aS*),3aα,8aα)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine
• (-)-2,6-Bis[2-{3aS-(2(3'aR*,8'aS*),3aα,8aα)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole}]pyridine,97%
• (3aS,3'aS,8aR,8'aR)-2,2'-(2,6-pyridinediyl)bis[3a,8a-dihydro-8H-Indeno[1,2-d]oxazole
• 2,6-Bis((3aS,8aR)-8,8a-dihydro-3aH-indeno[1,2-d]oxazol-2-yl)pyridine
• (-)-2,6-Bis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-d]oxazolin-2-yl]pyridine, min. 97% Indenyl-PYBOX